Loading
Abiomed Inc Stock: price and insider trades · United States
Abiomed Inc: what insiders have been doing
Abiomed Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at Abiomed Inc has published a filing in the past twelve months. The most recent one dates from 27 December 2022.
Since 2016, the database holds no purchases and 20 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
106
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€9M
20 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended March 2022 · cache
Income statement
Revenue919.8M
Net income121.7M13.2% margin
Last declaration on 27 December 2022
Declarations106 total
1,721 shares0Common Stock, $.01 par valueSEC:0001415889-22-012998:0
1,659 shares0Common Stock, $.01 par valueSEC:0001415889-22-013007:0
23,484 shares0Common Stock, $.01 par valueSEC:0001415889-22-013015:0
166,670 shares0Common Stock $.01 par valueSEC:0001415889-22-013017:0
7,410 shares0Common Stock, $.01 par valueSEC:0001415889-22-012995:0
3,255 shares0Common Stock, $0.01 par valueSEC:0001415889-22-013031:0
8,406 shares0Common Stock $.01 par valueSEC:0001415889-22-013027:0
243,962 shares0Common Stock $.01 par valueSEC:0001415889-22-013017:1
11,335 shares0Common Stock, $0.01 par valueSEC:0001415889-22-013031:1
12,237 sharesCommon Stock, $0.01 par valueSEC:0001415889-22-013011:0
123,370 sharesCommon Stock, $0.01 par valueSEC:0001415889-22-013033:0
14,166 sharesCommon Stock, $0.01 par valueSEC:0001415889-22-013029:0
6,357 sharesCommon Stock, $.01 par valueSEC:0001415889-22-013000:0
9,285 sharesCommon Stock, $0.01 par valueSEC:0001415889-22-013005:0
14 shares0Common Stock, $.01 par valueSEC:0001415889-22-012843:0
1 shares0Common Stock $.01 par valueSEC:0001415889-22-012840:0
1,133 shares@ US$374.182825.6% of flowCommon Stock, $0.01 par valueSEC:0001415889-22-011489:0
1,548 shares@ US$373.9931.7% of flowCommon Stock, $0.01 par valueSEC:0001415889-22-011176:0
5,164 shares@ US$373.9943.8% of flowCommon Stock $.01 par valueSEC:0001415889-22-011180:0
2,000 shares@ US$373.7143.9% of flowCommon Stock, $0.01 par valueSEC:0001415889-22-011186:0
1,548 shares@ US$373.9974.6% of flowCommon Stock, $.01 par valueSEC:0001415889-22-011183:0
1,548 shares@ US$373.9934.0% of flowCommon Stock, $0.01 par valueSEC:0001415889-22-011186:1
1,000 shares@ US$379.3867.2% of flowCommon Stock, $.01 par valueSEC:0001415889-22-011063:0
263 shares@ US$377.825.4% of flowCommon Stock, $0.01 par valueSEC:0001415889-22-011061:0
1,843 shares@ US$223.9066.2% of flowCommon Stock $.01 par valueSEC:0001415889-22-011065:0
25 of 106 declarations
About Abiomed Inc
Abiomed Inc. was historically a U.S. specialist in circulatory support and cardiac assist technologies and is now part of Johnson & Johnson MedTech. Prior to its acquisition, the company was listed on the U.S. NASDAQ market under the ticker ABMD and was best known for its Impella platform, a family of minimally invasive percutaneous heart pumps designed to temporarily unload the heart, maintain blood flow, and support patient recovery. Abiomed was founded in 1981 in Danvers, Massachusetts, with an original ambition to develop the world’s first artificial heart. Over time, its strategic focus evolved toward “native heart recovery,” meaning helping the patient’s own heart recover rather than permanently replacing cardiac function.
The core product portfolio centered on the Impella family, including Impella CP, Impella 5.5, and Impella RP, along with SmartAssist-enabled versions and related clinical support offerings. These devices are used in high-risk PCI and cardiogenic shock settings, which positions ABIOMED in a highly specialized, clinically driven medtech niche. That niche is attractive from a competitive standpoint because it combines regulatory barriers, procedure-level expertise, and recurring clinician training and support. Abiomed also emphasized on-site, on-call, and online clinical services, which reinforced customer adoption and differentiated the platform from more commoditized medical-device offerings.
Read moreShow less
Geographically, ABIOMED was anchored in the United States, with headquarters in Danvers, Massachusetts, and a steadily expanding international footprint, including Europe and Japan. The company’s history was marked by sustained innovation, a meaningful patent base, and a strong clinical-development pipeline. For investors, the most important recent milestone is the acquisition by Johnson & Johnson, announced in 2022 and completed on December 22, 2022. Following closing, Abiomed ceased to exist as an independent publicly traded company, and the business now operates as a standalone platform within Johnson & Johnson MedTech.
From an equity-investor perspective, ABIOMED is therefore best understood as a former U.S. growth medtech company whose value proposition rested on breakthrough cardiovascular technology, strong clinical adoption, and intellectual-property depth. Although ABMD is no longer an active listed stock, Abiomed’s operating legacy remains strategically important inside Johnson & Johnson’s cardiovascular portfolio in the United States and internationally.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
